Home » USA Broker Ratings » Opko Health – Consensus Indicates Potential -6.6% Downside

Opko Health – Consensus Indicates Potential -6.6% Downside

Opko Health with ticker code (OPK) have now 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 6 and 3.8 with the average target price sitting at 4.95. Now with the previous closing price of 5.3 this is indicating there is a potential downside of -6.6%. The 50 day MA is 3.6 and the 200 day moving average is 2.26. The market capitalisation for the company is $3,918m. Company Website: http://www.opko.com

OPKO Health, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company’s Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health was incorporated in 1991 and is headquartered in Miami, Florida.

Join us on our new LinkedIn page

Follow us on LinkedIn